Co-Diagnostic Enters into Agreement with Arches Research to Expand COVID-19 Testing
September 11, 2020
Co-Diagnostics, a Salt Lake City company that was out of the gate early with a molecular COVID-19 test, announced this week that it has entered into an agreement with another Salt Lake City based company, Arches Research, a CLIA laboratory and subsidiary of PolarityTE to expand Arches’ COVID-19 testing services using Co-Diagnostics’ Logix Smart™ COVID-19 test kit.
Dwight Egan, CEO of Co-Diagnostics, remarked, “We are pleased to have this opportunity to further expand our relationship with one of our valued CLIA lab clients to help meet demand for COVID-19 testing. Arches has been an important customer in the ongoing battle against the coronavirus, and we expect this agreement will also create opportunities for sales of additional molecular diagnostic products in our development pipeline, including our upcoming Logix Smart Flu A/Flu B/COVID-19 test kit.”
“It is particularly notable when two BioUtah companies join forces to expand testing capacity for COVID-19 in Utah, which is critical to a safe reopening of our communities and economy,” added Kelvyn Cullimore, president and CEO of BioUtah.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
